As of 2026-03-17, the EV/EBITDA ratio of Profound Medical Corp (PRN.TO) is -7.43. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. PRN.TO's latest enterprise value is 301.10 mil CAD. PRN.TO's TTM EBITDA according to its financial statements is -40.51 mil CAD. Dividing these 2 quantities gives us the above PRN.TO EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.0x - 18.9x | 13.4x |
| Forward P/E multiples | 16.7x - 21.1x | 18.9x |
| Fair Price | (17.69) - (20.30) | (17.10) |
| Upside | -325.9% - -359.2% | -318.5% |
| Date | EV/EBITDA |
| 2026-03-11 | -7.66 |
| 2026-03-10 | -7.31 |
| 2026-03-09 | -7.04 |
| 2026-03-06 | -7.05 |
| 2026-03-05 | -10.52 |
| 2026-03-04 | -10.69 |
| 2026-03-03 | -10.55 |
| 2026-03-02 | -10.60 |
| 2026-02-27 | -10.91 |
| 2026-02-26 | -11.33 |
| 2026-02-25 | -10.66 |
| 2026-02-24 | -10.12 |
| 2026-02-23 | -10.03 |
| 2026-02-20 | -9.71 |
| 2026-02-19 | -9.84 |
| 2026-02-18 | -9.96 |
| 2026-02-17 | -9.49 |
| 2026-02-13 | -9.21 |
| 2026-02-12 | -8.74 |
| 2026-02-11 | -8.90 |
| 2026-02-10 | -8.88 |
| 2026-02-09 | -8.99 |
| 2026-02-06 | -9.06 |
| 2026-02-05 | -9.03 |
| 2026-02-04 | -9.64 |
| 2026-02-03 | -10.03 |
| 2026-02-02 | -11.26 |
| 2026-01-30 | -10.77 |
| 2026-01-29 | -10.42 |
| 2026-01-28 | -10.82 |
| 2026-01-27 | -11.05 |
| 2026-01-26 | -11.23 |
| 2026-01-23 | -11.45 |
| 2026-01-22 | -11.36 |
| 2026-01-21 | -11.67 |
| 2026-01-20 | -11.47 |
| 2026-01-19 | -12.18 |
| 2026-01-16 | -12.44 |
| 2026-01-15 | -12.34 |
| 2026-01-14 | -11.37 |
| 2026-01-13 | -12.42 |
| 2026-01-12 | -13.03 |
| 2026-01-09 | -12.55 |
| 2026-01-08 | -12.63 |
| 2026-01-07 | -12.03 |
| 2026-01-06 | -11.32 |
| 2026-01-05 | -11.29 |
| 2026-01-02 | -11.17 |
| 2025-12-31 | -11.43 |
| 2025-12-30 | -10.41 |